HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • LipoADC™ Platform – K1
    • TRAFsome™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • LipoADC™ Platform – K1
    • TRAFsome™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (12)
  • Publications (14)
  • References (21)
  • Uncategorized (6)

Recent Posts

Post placeholder image
September 18, 2024

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 16, 2024

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 4, 2024

HighField Biopharmaceuticals Company Profile – 2024

by PJWCreative
Post placeholder image
September 3, 2024

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

by PJWCreative
Post placeholder image
August 8, 2024

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

by PJWCreative
Post placeholder image
June 24, 2024

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
August 8, 2024 in Publications

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

PJWCreative 0 Like Post Comments Off on ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

Click here

Read More

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin
HIGHfield_logo_horizontal_FINAL_trans

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

HIGHFIELD_web_LI_icon_x75

© 2024 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文